Give HCPs a proactive way to reach your field team: Add inbound
Bio Pharma Dive
MARCH 18, 2024
HCPs today want inbound channels for help when they need it. See how you can meet their preferences.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Bio Pharma Dive
MARCH 18, 2024
HCPs today want inbound channels for help when they need it. See how you can meet their preferences.
Bio Pharma Dive
MARCH 15, 2024
The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MARCH 14, 2024
The deal gives AstraZeneca a prospect in late-stage testing for parathyroidism and bolsters a rare disease portfolio that mainly consists of drugs from Alexion.
Bio Pharma Dive
MARCH 11, 2024
Justin Klee and Joshua Cohen spoke to BioPharma Dive about the next steps for their company, which is considering pulling its only product from market after the drug failed a confirmatory study in ALS.
Bio Pharma Dive
FEBRUARY 26, 2024
Zealand shares rose by more than one-third on the data, which provide further evidence so-called incretin drugs could help treat people with the liver disease.
Bio Pharma Dive
FEBRUARY 22, 2024
Richard Gonzalez led AbbVie to become one of the largest pharmaceutical firms, but the company's pricing and patent tactics brought criticism and scrutiny, too.
Bio Pharma Dive
FEBRUARY 22, 2024
The startup’s Series C round will support a clinical-stage drug the company thinks could address some of the weaknesses of other KRAS-targeting medicines.
Bio Pharma Dive
FEBRUARY 7, 2024
The new firm intends to carefully select its startups and fund them for the long haul. “We're not a company formation factory,” said Aaron Kantoff, the firm’s co-founder.
Bio Pharma Dive
FEBRUARY 6, 2024
The deals hand Novartis a myelofibrosis drug with uncertain regulatory prospects and Incyte a marketed lymphoma medicine that hasn’t sold well.
Bio Pharma Dive
FEBRUARY 6, 2024
The life sciences investor has backed a number of startups working on technologies for delivering and manufacturing cell and gene medicines.
Bio Pharma Dive
FEBRUARY 5, 2024
In a related deal, Novo Holdings subsidiary Novo Nordisk will buy three major Catalent factories for $11 billion as it works to keep pace with demand for its obesity and diabetes medicines.
Bio Pharma Dive
FEBRUARY 2, 2024
A regulatory filing shows the firm is putting together a new multibillion-dollar fund, roughly two years after raising a similar amount.
Bio Pharma Dive
JANUARY 18, 2024
The company said it has secured agreement from labor representatives in Germany for job cuts that will shed “many managerial employees.
Bio Pharma Dive
JANUARY 18, 2024
The biotech will receive $500 million upon FDA approval of its rare disease drug acoramidis after selling 5% sales royalties to two investment firms.
Bio Pharma Dive
JANUARY 18, 2024
Called Advanced Medicine Partners, the new company will offer specialized cell and gene therapy manufacturing services to biotech and pharma clients.
Bio Pharma Dive
JANUARY 16, 2024
A stock market run and a flurry of dealmaking have buoyed a sector that spent much of 2023 in a downturn. Can the momentum last?
Bio Pharma Dive
JANUARY 16, 2024
The restructuring adds to a wave of industry layoffs and makes the Californian biotech at least third this year to reduce its workforce by at least 50%.
Bio Pharma Dive
DECEMBER 11, 2023
AbbVie’s blockbuster medicine topped a list of treatments that, combined, elevated U.S. healthcare spending by $1.3 billion in 2022, according to the price watchdog’s latest yearly report.
Bio Pharma Dive
DECEMBER 11, 2023
Research from Everest Group shows how life sciences leaders are investing in process mining to speed time-to-market, improve regulatory compliance and drive innovation.
Bio Pharma Dive
DECEMBER 9, 2023
Follow-up data continue to show Lyfgenia can address the pain crises people with sickle cell experience, although Bluebird’s therapy will be compared to Vertex and CRISPR Therapeutics’ Casgevy, which was also approved Friday.
Bio Pharma Dive
NOVEMBER 20, 2023
Called Evinova, the unit will operate as a separate business within AstraZeneca, which sees digital health solutions as a market primed for growth.
Bio Pharma Dive
NOVEMBER 20, 2023
The regulator plans to convene an advisory panel to discuss an expanded indication for Abecma, presenting another hurdle for Bristol Myers and partner 2seventy bio.
Bio Pharma Dive
NOVEMBER 20, 2023
Company shares fell by one-fifth after study monitors called for halting a planned 18,000-person trial because Bayer’s experimental drug wasn’t working as well as Eliquis.
Bio Pharma Dive
OCTOBER 17, 2023
Tuesday’s earnings were the first since J&J officially split off its consumer drug business, now the publicly traded company Kenvue.
Bio Pharma Dive
OCTOBER 17, 2023
The Merck drug leads competitors Opdivo and Imfinzi into a new immunotherapy setting, which aims to improve outcomes following the surgical removal of tumors.
Bio Pharma Dive
OCTOBER 17, 2023
The Danish drugmaker's innovation hub in Boston has teamed up with the Broad Institute, Mass General Brigham, Harvard and Yale, expanding its research into cardiometabolic diseases.
Bio Pharma Dive
OCTOBER 16, 2023
A few key meetings remain this year, like ESMO and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.
Bio Pharma Dive
OCTOBER 16, 2023
Worth up to $1.3 billion, the deal with Singapore-based KBP Biosciences builds the Ozempic maker’s armory of metabolic disease drugs.
Bio Pharma Dive
OCTOBER 16, 2023
There are many common reasons clinical trials fail, including failure to demonstrate efficacy, safety concerns, issues with inclusion and exclusion criteria and patient recruitment. Follow these five steps to increase the odds of clinical trial success.
Bio Pharma Dive
OCTOBER 16, 2023
In an industry where the convergence of cutting-edge science and a human-centered approach is equally imperative, Worldwide Clinical Trials has found the sweet spot, delivering excellence in the clinical trial experience.
Bio Pharma Dive
OCTOBER 13, 2023
Following a re-examination, the EMA again concluded that Albrioza — known as Relyvrio in the U.S. — should not be cleared for the European market.
Bio Pharma Dive
OCTOBER 13, 2023
The awards, to biotechs Gritstone, Codagenix and CastleVax, are part of the program’s plan to develop vaccines with broader or longer-lasting benefits.
Bio Pharma Dive
OCTOBER 13, 2023
Acquired with the buyout of Arena Pharmaceuticals, Velsipity enters a competitive market for ulcerative colitis pills.
Bio Pharma Dive
OCTOBER 12, 2023
The company expects to deliver first results next year from the early-stage study of people with myotonic dystrophy type 1.
Bio Pharma Dive
SEPTEMBER 7, 2023
The Series B round makes Mariana one of the best funded private companies in a growing group of biotechs working on new radiopharmaceutical therapies.
Bio Pharma Dive
SEPTEMBER 5, 2023
The signals of a return to growth are emerging. As commercial leaders gear up for 2024 planning, they must prepare to fight for resources in a budget constrained environment.
Bio Pharma Dive
SEPTEMBER 1, 2023
The settlement between Amgen and the FTC may reassure those in the industry who feared a more activist regulator would gum up dealmaking.
Bio Pharma Dive
AUGUST 31, 2023
Yoo, who leads health tech investment at venture capital firm Andreessen Horowitz, outlined her fintech investment thesis and why the healthcare industry is at an inflection point.
Bio Pharma Dive
AUGUST 31, 2023
Houman Ashrafian, currently a scientific advisor at SV Health Investors, will fill the role left by John Reed, who oversaw the transformation of research and development during his five years at Sanofi.
Bio Pharma Dive
JULY 28, 2023
The report, from the new startup-focused division of HSBC, found that investment in drugmaking “platforms” is declining as venture firms turn to safer bets.
Bio Pharma Dive
JULY 27, 2023
Medicxi is the latest biotech investor to announce a new investment fund in 2023, despite a turbulent market that’s challenged many startups.
Bio Pharma Dive
JULY 26, 2023
The cost cuts at the nearly 30-year-old biotech are part of plans to seek a “strategic transaction” for the company’s only remaining drug prospect.
Bio Pharma Dive
JULY 26, 2023
Led by Vivek Ramaswamy's brother, Kriya has now raised over $600 million to fund gene therapy research spanning ophthalmology, neurology and metabolic disease.
Bio Pharma Dive
JULY 26, 2023
The startup is the latest young company to emerge with plans to make production of cell-based medicines easier for researchers and biotechs.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content